NASDAQ:SYNHSyneos Health Stock Price, Forecast & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYNH stock has decreased by 28.6% and is now trading at $40.89. View which stocks have been mosted impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Syneos Health.

Syneos Health Inc (NASDAQ:SYNH) issued its quarterly earnings results on Thursday, February, 20th. The company reported $1.03 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.01 by $0.02. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. Syneos Health had a return on equity of 10.12% and a net margin of 2.81%. Syneos Health's quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.95 EPS. View Syneos Health's earnings history.

Syneos Health issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.65. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.94 billion.

10 brokerages have issued twelve-month price objectives for Syneos Health's shares. Their forecasts range from $42.00 to $82.00. On average, they anticipate Syneos Health's stock price to reach $62.20 in the next year. This suggests a possible upside of 52.1% from the stock's current price. View analysts' price targets for Syneos Health.

Media headlines about SYNH stock have trended very negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syneos Health earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutSyneos Health.

Syneos Health saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 6,199,900 shares, a decline of 6.3% from the February 27th total of 6,620,000 shares. Based on an average daily trading volume, of 1,569,000 shares, the short-interest ratio is currently 4.0 days. Approximately 10.0% of the company's shares are short sold. View Syneos Health's Current Options Chain.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PPD (PPD), PRA Health Sciences (PRAH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (PGEN), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Solaredge Technologies (SEDG), CVS Health (CVS), Square (SQ), Constellation Brands (STZ), UnitedHealth Group (UNH), Verizon Communications (VZ) and JD.Com (JD).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs, Jonathan Olefson and Paul Colvin. View institutional ownership trends for Syneos Health.

SYNH stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, Jonathan Olefson, and Paul Colvin. View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $40.89.

Syneos Health has a market capitalization of $4.26 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe. View additional information about Syneos Health.

The official website for Syneos Health is http://www.syneoshealth.com/.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]